HFA-BDP治疗的哮喘患儿的肺功能变化
2011/06/17
摘要
研究目的：哮喘指南指出，哮喘控制良好的一个目标是肺功能达到正常或接近正常。本试验对外周气道功能下降的慢性持续性哮喘患儿，在采用氢氟烷-134a二丙酸倍氯米松(HFA-BDP)超细气溶胶替代传统皮质激素吸入治疗后的疗效进行评价。
研究设计和研究机构：对中度持续性哮喘患儿的肺功能和临床信息进行研究，这些患儿定期在美国肯塔基州路易斯维尔Kosair儿童医院肺科门诊就诊。
研究对象：共计20名稳定性哮喘患儿（7名女童和13名男童）入选，用力呼气流量位于25~75%肺活量(FEF25-75)。
干预：在初始评价后，每名受试者从传统的皮质激素吸入治疗转为HFA-BDP治疗。其他治疗同前。治疗至少3周后对患者的肺功能和临床状态进行再次评价。
结果：FEF25-75平均从50.75%增加至68.85%预测值(P<0.001)。第一秒用力呼气体积（FEV1）也从84.6%增加至93.8%预测值(P=0.001)。哮喘症状未见显著变化。
结论：与传统皮质激素吸入治疗相比，哮喘患儿采用HFA-BDP治疗能显著改善大气道和外周气道气流，而不影响哮喘控制。
（苏楠 审校）
Pediatr Pulmonol. 2011 Apr 4. doi: 10.1002/ppul.21449. [Epub ahead of print]
Lung function changes in asthmatic children treated with HFA-BDP.
Eid N, Morton R.
Department of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky. nseid@louisville.edu.
Abstract
STUDY OBJECTIVES: Asthma guidelines suggest that normal or near normal lung function should be one of the goals for good asthma control. Therefore, children with chronic persistent asthma and reduced peripheral airway function were assessed after the replacement of conventional inhaled corticosteroids (ICS) with an extrafine aerosol formulation, hydrofluoroalkane-134a beclomethoasone diproprionate (HFA-BDP).
DESIGN AND SETTING: Lung function and clinical details were studied in children with moderate persistent asthma who regularly attended the pediatric pulmonary outpatient clinic at Kosair Children’s Hospital, Louisville, Kentucky, USA.
SUBJECTS: A total of 20 children, 7 girls and 13 boys, with stable asthma but reduced forced expiratory flows between 25% and 75% of vital capacity (FEF(25-75) ) were included in the study.
INTERVENTION: After the initial assessment, each subject was switched from conventional ICS to HFA-BDP. All other medications remained the same. Reassessment of lung function and clinical status was performed at least 3 weeks after the intervention.
RESULTS: FEF(25-75) increased from a mean of 50.75% to 68.85% predicted (P < 0.001). Forced expiratory volume in 1 sec (FEV(1)) also increased significantly from 84.6% to 93.8% predicted (P = 0.001). No changes asthma symptoms were observed.
CONCLUSION: Compared to conventional ICS, the use of HFA-BDP in asthmatic children significantly improves airflow in both the large and the peripheral airways without loss of asthma control.
Pediatr Pulmonol. 2011 Apr 4. doi: 10.1002/ppul.21449. [Epub ahead of print]
研究目的：哮喘指南指出，哮喘控制良好的一个目标是肺功能达到正常或接近正常。本试验对外周气道功能下降的慢性持续性哮喘患儿，在采用氢氟烷-134a二丙酸倍氯米松(HFA-BDP)超细气溶胶替代传统皮质激素吸入治疗后的疗效进行评价。
研究设计和研究机构：对中度持续性哮喘患儿的肺功能和临床信息进行研究，这些患儿定期在美国肯塔基州路易斯维尔Kosair儿童医院肺科门诊就诊。
研究对象：共计20名稳定性哮喘患儿（7名女童和13名男童）入选，用力呼气流量位于25~75%肺活量(FEF25-75)。
干预：在初始评价后，每名受试者从传统的皮质激素吸入治疗转为HFA-BDP治疗。其他治疗同前。治疗至少3周后对患者的肺功能和临床状态进行再次评价。
结果：FEF25-75平均从50.75%增加至68.85%预测值(P<0.001)。第一秒用力呼气体积（FEV1）也从84.6%增加至93.8%预测值(P=0.001)。哮喘症状未见显著变化。
结论：与传统皮质激素吸入治疗相比，哮喘患儿采用HFA-BDP治疗能显著改善大气道和外周气道气流，而不影响哮喘控制。
（苏楠 审校）
Pediatr Pulmonol. 2011 Apr 4. doi: 10.1002/ppul.21449. [Epub ahead of print]
Lung function changes in asthmatic children treated with HFA-BDP.
Eid N, Morton R.
Department of Pediatrics, University of Louisville School of Medicine, Louisville, Kentucky. nseid@louisville.edu.
Abstract
STUDY OBJECTIVES: Asthma guidelines suggest that normal or near normal lung function should be one of the goals for good asthma control. Therefore, children with chronic persistent asthma and reduced peripheral airway function were assessed after the replacement of conventional inhaled corticosteroids (ICS) with an extrafine aerosol formulation, hydrofluoroalkane-134a beclomethoasone diproprionate (HFA-BDP).
DESIGN AND SETTING: Lung function and clinical details were studied in children with moderate persistent asthma who regularly attended the pediatric pulmonary outpatient clinic at Kosair Children’s Hospital, Louisville, Kentucky, USA.
SUBJECTS: A total of 20 children, 7 girls and 13 boys, with stable asthma but reduced forced expiratory flows between 25% and 75% of vital capacity (FEF(25-75) ) were included in the study.
INTERVENTION: After the initial assessment, each subject was switched from conventional ICS to HFA-BDP. All other medications remained the same. Reassessment of lung function and clinical status was performed at least 3 weeks after the intervention.
RESULTS: FEF(25-75) increased from a mean of 50.75% to 68.85% predicted (P < 0.001). Forced expiratory volume in 1 sec (FEV(1)) also increased significantly from 84.6% to 93.8% predicted (P = 0.001). No changes asthma symptoms were observed.
CONCLUSION: Compared to conventional ICS, the use of HFA-BDP in asthmatic children significantly improves airflow in both the large and the peripheral airways without loss of asthma control.
Pediatr Pulmonol. 2011 Apr 4. doi: 10.1002/ppul.21449. [Epub ahead of print]
上一篇：
家长启动的口服皮质激素治疗在学龄前儿童喘息和学龄期儿童哮喘治疗中的作用
下一篇：
哮喘控制较差儿童的阻塞性睡眠呼吸暂停：增殖腺扁桃体切除术的疗效
